GlassScriptPhysician profile
Susannah Macdonald Becker
NPI 1124254412
$3,253.50
in general payments reported to CMS, 2019-2025
28 companies · $598 in 2025
The $598 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $810 · 2020: $73.04 · 2021: $459 · 2022: $623 · 2023: $372 · 2024: $319 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,288.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $778.13 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Novo Nordisk INC | $600.13 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $240.52 | 2021-2022 | |
| Amgen INC. | $215.73 | 2019-2021 | |
| Insulet Corporation | $154.20 | 2019-2025 | Omnipod |
| Boston Scientific Corporation | $145.12 | 2024 | Wavewriter Alpha Prime 16 |
| Sequel Med Tech, LLC | $137.55 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $134.67 | 2023-2024 | Gvoke Hypopen, Recorlev |
| Horizon Therapeutics Plc | $124.27 | 2022 | |
| Tandem Diabetes Care, INC. | $110.17 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic Minimed, INC. | $102.08 | 2019 | |
| Sanofi-Aventis U.S. LLC | $68.86 | 2019-2023 | |
| Mannkind Corporation | $59.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $51.74 | 2019 | |
| Abbott Laboratories | $49.90 | 2022-2023 | Freestyle Libre 3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $44.09 | 2025 | |
| Abbvie INC. | $34.45 | 2019-2024 | |
| Lilly USA, LLC | $26.17 | 2020-2022 | |
| Embecta Corp. | $25.60 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Valeritas, INC. | $24.73 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.73 | 2023 | Synjardy, Jardiance |
| Medtronic, INC. | $18.79 | 2022 | |
| Lifescan, INC. | $16.51 | 2020 | |
| Cequr Corporation | $15.64 | 2022 | |
| Merck Sharp & Dohme LLC | $15.05 | 2022 | |
| Shire North American Group INC | $14.69 | 2019 | |
| Vivus LLC | $13.60 | 2019 | |
| Currax Pharmaceuticals LLC | $11.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susannah Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.